Tussey, L, Song, L. and S. Umlauf. 2016. United States Patent Application 20160166671
Fusion proteins include full-length flagellin or portions of flagellin fused to at least one Clostridium difficile antigen. Fusion proteins can include a first Clostridium difficile antigen that replaces at least a portion or the entirety of domain 3 of flagellin and a second Clostridium difficile antigen fused to the carboxy terminal amino acid of flagellin. Fusion proteins can also include at least one Clostridium difficile antigen fused to the most carboxy terminus of portions of flagellin or full length flagellin. Methods that employ fusion proteins are administered to humans to ameliorate Clostridium difficile associated disease.
*Note: Chicken anti-Clostridium difficile toxins used in this publication were manufactured by Gallus Immunotech Inc.